From: Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases
 | Overall | Cohort | ||||||
---|---|---|---|---|---|---|---|---|
HER2-negative (N = 9) | HER2-positive (N = 29) | |||||||
Grade | Grade | |||||||
N | 1 | 2 | 3 | 1 | 2 | 3 | 4 | |
AE name | ||||||||
 Hemoglobin | 29 (76%) | 4 (44%) | 3(33%) |  | 10 (34%) | 11 (38%) | 1 (3%) |  |
 Fatigue | 28 (74%) | 1 (11%) | 3(33%) | 2(22%) | 9 (31%) | 9 (31%) | 4 (14%) |  |
 Platelets | 28 (74%) | 3 (33%) | 3(33%) |  | 6 (21%) | 12 (41%) | 3 (10%) | 1 (3%) |
 AST | 23 (61%) | 5 (56%) | 1(11%) |  | 15 (52%) |  | 2 (7%) |  |
 | 22 (58%) | 2 (22%) | 1(11%) |  | 3 (10%) | 13 (45%) | 3 (10%) |  |
 Head/headache | 20 (53%) | 4 (44%) |  |  | 10 (34%) | 6 (21%) |  |  |
 Hyperglycemia | 18 (47%) | 3 (33%) | 1(11%) |  | 12 (41%) | 2 (7%) |  |  |
 Leukocytes | 18 (47%) |  |  |  | 4 (14%) | 14 |  |  |
 Nausea | 17 (45%) | 1 (11%) | 1(11%) |  | 13 (45%) | 2 (7%) |  |  |
 ALT | 14 (37%) | 3 (33%) | 1(11%) |  | 8 (28%) |  | 2 (7%) |  |
 Constipation | 14 (37%) | 3(33%) | 1(11%) |  | 7 (24%) | 3 (10%) |  |  |
 Neuropathy-sensory | 14 (37%) | 3(33%) |  |  | 9 (31%) | 2 (7%) |  |  |
 Nose, hemorrhage | 12 (32%) | 1(11%) |  |  | 9 (31%) | 2 (7%) |  |  |
 Alkaline phosphatase | 11 (29%) |  |  |  | 9 (31%) | 2 (7%) |  |  |
 Diarrhea w/o prior colostomy | 11 (29%) | 1(11%) | 1(11%) |  | 7 (24%) | 2 (7%) |  |  |
 Cough | 9 (24%) |  |  |  | 8 (28%) | 1 (3%) |  |  |
 Hypertension | 9 (24%) |  |  |  | 6 (21%) | 2 (7%) | 1 (3%) |  |
 Alteration in bone age | 8 (21%) |  |  |  | 6 (21%) | 2 (7%) |  |  |
 Proteinuria | 8 (21%) | 1(11%) |  |  | 6 (21%) | 1 (3%) |  |  |
 Extremity-limb, pain | 7 (18%) |  |  |  | 4 (14%) | 2 (7%) | 1 (3%) |  |
 Alopecia | 6 (16%) |  | 1(11%) |  |  | 4 (14%) | 1 (3%) |  |
 Hyponatremia | 6 (16%) |  |  |  | 5 (17%) |  | 1 (3%) |  |
 Joint, pain | 6 (16%) |  |  |  | 3 (10%) | 2 (7%) | 1 (3%) |  |
 Vomiting | 6 (16%) | 2(22%) | 1(11%) |  | 2 (7%) | 1 (3%) |  |  |
 Allergic reaction | 5 (13%) |  |  |  | 1 (3%) | 4 (14%) |  |  |
 Back, pain | 5 (13%) |  |  |  | 4 (14%) | 1 (3%) |  |  |
 Dizziness | 5 (13%) |  |  |  | 2 (7%) | 3 (10%) |  |  |
 Infection Grade 0–2, upper airway | 5 (13%) |  |  |  | 4 (14%) | 1 (3%) |  |  |
 Left ventricular systolic dysfunction | 5 (13%) |  |  |  |  | 5 (17%) |  |  |
 Pain-other | 5 (13%) | 1(11%) | 1(11%) |  | 1 (3%) | 2 (7%) |  |  |
 Rectum, hemorrhage | 5 (13%) |  |  |  | 4 (14%) | 1 (3%) |  |  |
 Bone, pain | 4 (11%) |  |  |  | 4 (14%) |  |  |  |
 CNS, hemorrhage | 4 (11%) | 1(11%) | 1(11%) |  | 2 (7%) |  |  |  |
 Constitutional, other | 4 (11%) |  |  |  | 3 (10%) | 1 (3%) |  |  |
 Creatinine | 4 (11%) | 2(22%) |  |  | 2 (7%) |  |  |  |
 GI-other | 4 (11%) |  |  |  | 4 (14%) |  |  |  |
 Hypocalcemia | 4 (11%) |  |  |  | 4 (14%) |  |  |  |
 Hypokalemia | 4 (11%) | 1(11%) |  |  | 3 (10%) |  |  |  |
 Metabolic/laboratory-other | 4 (11%) | 2(22%) | 1(11%) |  | 1 (3%) |  |  |  |
 Skin-other | 4 (11%) | 2(22%) |  |  | 1 (3%) | 1 (3%) |  |  |
 Throat/pharynx/larynx, pain | 4 (11%) |  |  |  | 4 (14%) |  |  |  |